Biosimilars can help reduce the high cost of oncology medicines spending1
Oncology innovation is booming, but costly for the healthcare system1,2
US oncology medicines spending continues to rise2

*Costs through 2026 are based on data reported by the IQVIA Oncology Link from April 2022. Costs beyond 2022 are projected growth based on a CAGR of 10.6% in the next 5 years.2

CAGR=compound annual growth rate; G-CSF=granulocyte colony-stimulating factor.
References: 1. IQVIA Institute for Human Data Science. Global oncology trends 2018: innovation, expansion and disruption. https://www.iqvia.com/institute/reports/global-oncology-trends-2018. Accessed May 24, 2023. 2. IQVIA Institute for Human Data Science. Global oncology trends 2022: outlook to 2026. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2022. Accessed May 24, 2022. 3. IQVIA Institute for Human Data Science. Global oncology trends 2019: therapeutics, clinical development and health system implications. https://www.iqvia.com/institute/reports/global-oncology-trends-2019. Accessed June 12, 2023. 4. Socal M, Ballreich J, Chyr L, Anderson G. Biosimilar medications—savings opportunities for large employers. A report for ERIC—the ERISA Industry Committee. Department of Health Policy and Management. John Hopkins Bloomberg School of Public Health. March 2020.